Latest News for: neurogenic

Edit

Statement of Changes in Beneficial Ownership (Form 4) (Neurogene Inc)

Public Technologies 25 Feb 2026
) FORM 4. Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b) ... See Instruction 10 ... OMB Number ... Neurogene Inc ... C/O NEUROGENE INC., 535 W 24TH STREET, 5TH FLOOR 3 ... C/O NEUROGENE INC ... Neurogene Inc.
Edit

Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Neurogene Inc)

Public Technologies 04 Feb 2026
4, 2026-- Neurogene Inc ... The Inducement Grant was granted as an inducement material to this individual entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4) ... About Neurogene ... [email protected].
Edit

Neurogenic Orthostatic Hypotension (nOH) Global Clinical Trials Market Review 2025: Region, Country (G7 & E7), ...

Nasdaq Globe Newswire 19 Jan 2026
This aids strategic investment decisions and optimizing strategies in the global Neurogenic Orthostatic Hypotension (nOH) landscape.
Edit

Neurogene 2026 JP Morgan Presentation (Neurogene Inc)

Public Technologies 14 Jan 2026
) EVERY BREAKTHROUGH BEGINS WITH BELIEF. 44th Annual J. P. Morgan Healthcare Conference January 2026. Rachel McMinn, Ph.D ... OUR MISSION ... OUR APPROACH ... 3 ... Neurogene is Positioned for Significant Value Inflection with Multiple Catalysts in 2026. 4 ... Neurogene Inc.
Edit

Neurogene Corporate Presentation January 2026 (Neurogene Inc)

Public Technologies 12 Jan 2026
) EVERY BREAKTHROUGH BEGINS WITH BELIEF. Corporate Presentation. January 2026. OUR MISSION ... OUR APPROACH. Biology-first design ... 3 ... Upcoming Milestones ... Neurogene is Positioned for Significant Value Inflection with Multiple Catalysts in 2026. 4 ... Neurogene Inc.
Edit

Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome (Neurogene Inc)

Public Technologies 12 Jan 2026
Neurogene to present at J.P ... 12, 2026-- Neurogene Inc ... A webcast of the presentation will be accessible from the Investor Relations section of Neurogene's website under events, where a replay of the event will also be available for a limited time.
Edit

Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome (Form 8-K) (Neurogene Inc)

Public Technologies 12 Jan 2026
) Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome ... Neurogene to present at J.P ... NEW YORK - January 12, 2026 - Neurogene Inc ... About Neurogene ... Neurogene Inc.
Edit

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Neurogene Inc)

Public Technologies 04 Dec 2025
4, 2025-- Neurogene Inc ... The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4) ... About Neurogene ... [email protected].
×